Navigation Links
Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
Date:2/9/2011

CRANBURY, N.J., Feb. 9, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the dosing of the first subject in a Phase 2 clinical trial designed to evaluate the co-administration of its investigational drug Amigal™ (migalastat hydrochloride) with enzyme replacement therapy (ERT) for Fabry disease.  This open-label Phase 2 study is investigating drug-drug interactions between Amigal and the ERTs Fabrazyme® and Replagal®.  Preclinical studies have demonstrated that coadministration of Amigal results in a prolonged circulating half-life of ERT, increased enzyme activity in cells, and greater substrate reduction in target tissues compared to that seen with ERT alone.  Amigal is being developed in collaboration with GlaxoSmithKline (GSK), as part of an alliance between GSK Rare Diseases and Amicus.

John F. Crowley, Chairman and CEO of Amicus, stated "The commencement of this clinical study is an important milestone for Amicus and for pharmacological chaperone technology.  Based on encouraging preclinical results we believe the co-administration of Amigal with ERT has the potential to provide significant benefit for people with Fabry disease.  The advancement of this approach is a part of our vision to provide two new treatment options for Fabry patients in the future—Amigal as a monotherapy or Amigal co-administered with ERT.  Finally, we also believe this study will provide us with valuable proof of concept for applying this approach to other lysosomal storage diseases and more broadly to other indications treated with therapeutic proteins."  

Phase 2 Study Design

The Phase 2 trial will evaluate the safety and pharmacokinetics of Amigal and ERT when co-administered in 18 male patients with Fabry disease, ages 18-65, who have been receiving ERT for at least one month bef
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... and NINGBO, China , ... the Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced ... development of generic pharmaceuticals, primarily targeting the ... the agreement, Amerigen and Menovo will jointly develop products ... States . Menovo will be responsible for manufacturing ...
(Date:8/27/2014)... Aug. 27, 2014 Ambit Biosciences (Nasdaq: AMBI ... drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, ... Care Conference to be held at The New York Palace ... September 3-4, 2014. Alan Fuhrman , Ambit,s ... lead drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, ...
(Date:8/27/2014)... WARSAW, Ind. , Aug. 27, 2014  Zimmer ... in musculoskeletal care, announced that it will be participating ... the Grand Hyatt in New York, New ... David Dvorak , President and CEO of Zimmer, will ... Binder , President and CEO of Biomet, will join ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Ambit Announces Participation At Baird 2014 Health Care Conference 2
(Date:8/27/2014)... August 27, 2014 Shawna's new book, ... is about Seed Digging, which a brand-new technique she ... models, yet works to bring permanent healing quickly. , ... and mental health disorders cured on a daily basis. ... own minds and find incredible inner peace with only ...
(Date:8/27/2014)... Best SEO Hosting, a well-known SEO Hosts Review Site, has ... and GoDaddy are the most recommended suppliers for webmasters from ... hosting (including VPS and cloud hosting). , As one ... serving hosting small business websites since 1998. With more than ... the hosting industry for its affordable and easy to manage ...
(Date:8/27/2014)... The Latinos In Action Festival 2014 is being ... Florida State Fair Grounds from 9am - 9pm. Latinos ... from around the world. Latinos in Action Festival is ... and Univision Mobile, a service provided by T-Mobile company. ... 4,000 people from different backgrounds, cultures and nationalities. Come ...
(Date:8/27/2014)... HealthDay Reporter WEDNESDAY, Aug. ... in a dark alley will likely never want to return ... attacked. But neuroscientists working with mice say they,ve discovered ... positive and negative emotions. And in rodent tests, they,ve manipulated ... In essence, they made once-reluctant mice want to return ...
(Date:8/27/2014)... Dallas, Texas (PRWEB) August 28, 2014 ... Market Outlook to 2020?, provides key market data on ... millions of US dollars, volume (in units) and average ... (Rigid Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), ... There are a number of advantages to the patient ...
Breaking Medicine News(10 mins):Health News:Shawna Burns, Counselor, Releases Debut Book, "Seed Digging," to Improve Lives of Children and Adults with Addictions and Mental Health Disorders 2Health News:Well-known SEO Hosts Review Site Top10BestSEOHosting.com Recommends iPage, Bluehost and GoDaddy To Webmasters 2Health News:Marc Anthony to Perform at "Nieves Productions" Latinos in Action Festival 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4
... Offered to Cancer Patients in HELIOS HospitalsBERLIN, March 10 ... Germany will gain access to the most modern radiotherapy ... that it is acquiring nine linear accelerators from Varian ... of them equipped with RapidArc(TM) technology for fast and ...
... are embracing technological advances, such as electronic medical records, ... their needs.Those are the results found in a recent ... The findings were published in the March/April issue of ... conducted the same survey back in 2004. Five years ...
... Inc. (TSX: DDS; NASDAQ: DDSS ) today announced ... will present at the Cowen and Company 29th Annual Health ... March 18, 2009 at 11:00 a.m. ET. , Interested parties ... the "Events" section of the homepage of the Company,s website ...
... Pressure Profile Systems, Inc. Combines Tactile and 3D ... Footbeds to ConsumersLOS ANGELES and SCOTTSDALE, Ariz., March ... (PPS) together with its partner eSoles, LLC, today ... (R) Kiosk Scanning System. The free-standing, ...
... KONG, March 10 /PRNewswire-Asia/ -- Obio Pharmaceutical Holdings Ltd,("Obio"/ ... of a drug,TG21, against main strains of influenza virus ... H5N1. The process leading to clinical,trials for TG21 has ... and will continue to engage prestigious institutions in USA ...
... Awareness of the KeepingYouWell.com Website for People Seeking Quality Care ... ... Blue Search Engine Marketing is pleased to announce Adventist Midwest Health ... on for a unique, highly targeted search engine optimization campaign, and ...
Cached Medicine News:Health News:Leading German Healthcare Group Selects Equipment and Software from Varian Medical Systems for Major Replacement Project 2Health News:Survey Results: Health Care Technology Advances as Physician Frustration Grows 2Health News:World's Most Advanced Foot Scanning Kiosk Made Available to Retailers by eSoles and Pressure Profile Systems, Inc. 2Health News:Obio Pharmaceutical Announced New Antiviral Drug Discovery to Combat Influenza Virus 2Health News:Obio Pharmaceutical Announced New Antiviral Drug Discovery to Combat Influenza Virus 3Health News:Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign 2Health News:Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign 3
... head design has been carefully considered with both ... head ensures the optimum viewing angle and the ... laser aligned for perfect focus where it is ... paper. This along with Keeler's wide angle ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
... 200S is the first hand-held ... of patented aspherical optics (U.S. ... of corrective lenses from 36 ... diopter steps. A perfectly-focused image ...
... The ophthalmoscope with superior aspherical optics. ... illumination and observation beam by means of ... iris reflex (Gullstrand-principle). The Beta 200 allows ... illuminated section of the retina even with ...
Medicine Products: